Clinical Trial Results:
Estudio de Fase 2, de 17 Semanas, Multicéntrico, Aleatorizado y Doble Ciego, Sobre la Eficacia de LY2140023 Combinado con Tratamiento Clínico Habitual Comparado con Placebo Combinado con Tratamiento Clínico Habitual, en Pacientes con Esquizofrenia con Síntomas Negativos Prominentes
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment with LY2140023 Combined with Standard of Care Compared to Placebo Combined with Standard of Care in the Treatment of Patients with Prominent Negative Symptoms of Schizophrenia
Summary
|
|
EudraCT number |
2009-016245-26 |
Trial protocol |
ES IT |
Global completion date |
28 Jun 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Jan 2018
|
First version publication date |
27 Jan 2018
|
Other versions |
|
Summary report(s) |
HBCO Approved CSR |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.